ClinicalTrials.gg
RecruitingNCT07323329Updated Jan 7, 2026

Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization

A Phase 2/3 interventional study of Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day. and DHEA plus folic acid 400mcg per day in Infertility and Infertility (IVF Patients), sponsored by Beni-Suef University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Beni-Suef University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing dehydroepiandrosterone in Infertility — 2 open to participants now, 2 under way, 1 of them phase 3. Dehydroepiandrosterone · Infertility.

Planned enrollment
6th of 13
165 · median 140
Started
2025
the only one that year
Phase 2/3
2 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Beni-Suef University

Among the 13 studies testing dehydroepiandrosterone in Infertility, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 2/3, and was the 13th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

2 of the 13 studies testing dehydroepiandrosterone in Infertility are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dehydroepiandrosterone

Dehydroepiandrosterone: first FDA approval 2016 (INTRAROSA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing dehydroepiandrosterone in Infertility, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder.

The main question it aims to answer is:

Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.

03

Conditions studied

  • Infertility
  • Infertility (IVF Patients)

Browse trials for

Keywords

  • Growth hormone
  • Infertility
  • IVF patients
  • Ovarian reserve
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At least two of the following three criteria had to be present after maximal stimulation:

  1. Advanced maternal age (>40 years) or any other risk factor for Poor Ovarian Response (POR).
  2. ≤3 oocytes with a conventional stimulation protocol).
  3. An abnormal ovarian reserve test [i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml].

Exclusion criteria

Exclusion Criteria:

  1. Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction.
  2. Any pelvic pathology such as hydrosalpinx, uterine anomaly.
  3. Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    Somatropin group

    Somatropin (4IU for 1 month) 1 S.C injection every 3 days for at least 1 month plus, folic acid 400mcg/day

    Drug: Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.

  • Experimental
    dehydroepiandrosterone

    dehydroepiandrosterone 50 mg twice per day for 12 weeks plus folic acid 400mcg per day

    Drug: DHEA plus folic acid 400mcg per day

  • Active comparator
    Standard care

    Patients will receive standard care will receive folic acid 400 mcg per day

    Dietary Supplement: control group

Interventions

  • DrugSomatropin (4IU for 1 month) plus, folic acid 400 mcg per day.

    Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.

  • DrugDHEA plus folic acid 400mcg per day

    Drug pages: DehydroepiandrosteroneStudies of DehydroepiandrosteroneDehydroepiandrosterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Folic AcidStudies of Folic AcidFolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day

  • Dietary supplementcontrol group

    Patients will receive folic acid 400 mcg per day

06

What researchers measure

Primary outcomes

  1. The number of mature oocyte

    Time frame: 12 weeks

Secondary outcomes

  1. pregnancy rate

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod. 2000 Oct;15(10):2129-32. doi: 10.1093/humrep/15.10.2129. PubMed 11006185 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2025
First posted
Jan 7, 2026
StartActual
Oct 10, 2025
Primary completionEst.
Oct 15, 2026
CompletionEst.
Nov 12, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07323329
Responsible party
Hasnaa Osama (Lecturer of Clinical Pharmacy, Beni-Suef University, Beni-Suef University) — Principal investigator
First posted
Jan 7, 2026
Start date
Oct 10, 2025
Primary completion
Oct 15, 2026 (estimated)
Completion
Nov 12, 2026 (estimated)
Last update
Jan 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dehydroepiandrosterone · Folic Acid

Start the discussion